Insider buying last 90 days
No open-market insider purchases were filed for MANE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Veradermics moves this week on positive 12-month Phase 3 "302" data for VDPHL01, its extended-release oral minoxidil for male pattern hair loss, with the company reporting the highest reported hair count in the program to date. The results, covering Part B of the trial in over 500 men with mild-to-moderate pattern hair loss, were presented on an investor call. Separately, commentary has flagged the stock's valuation, noting a 267.6% year-to-date surge and a price-to-book ratio of 7.1x versus the industry average, alongside a view that the stock traded undervalued near $128.60 relative to a $170.50 fair value estimate.
The stock closes at $143.95, up 3.7%, sitting above its 50-day moving average of $118.68 and near its 52-week high of $146.57, with 52-week low at $32. One-month return stands at 10%, three-month at 32.1% and six-month at 33.1%. The GekkoIndex reads 51.8, placing it in the Neutral zone, down 2.3 over five days. Gekko Fair Value is set at $128.47, putting the current price 12% above that level.
Earnings are scheduled for 10 November 2026, zero days away, placing the report inside a typical 20-trading-day holding window; the prior quarter posted an EPS of -0.58 against a -0.65 estimate, with a -1.5% reaction. One billionaire holder and one trailblazer holder are noted. Analyst coverage from 5 firms is unanimously rated buy, with a consensus target of $170.50, implying 18.4% consensus upside. Typical 20-day price movement runs 17.1%, worth noting given the imminent earnings date.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Veradermics scores 0 supportive, 2 mixed and 0 headwinds across the 2 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
0 supportive2 mixed0 headwinds
No data
Not enough price history for both moving averages.
See the chart58.1, Neutral
Reading 58.1 is in the Neutral zone.
See the GekkoIndex0.7% below
Price is within 5% of Gekko Fair Value (0.7% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyNo data
No confirmed report date on the calendar.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Veradermics closed at $129.66 on Nov 13, 2026, inside a 52-week range of $32.00 to $156.63.
Use the left and right arrow keys to read daily values.
Put MANE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Veradermics works on new drug candidates for skin and cosmetic conditions, with a pipeline built around treatments for pattern hair loss in both adults and children. Its best-known candidate is VDPHL01, a pill taken by mouth that does not rely on hormones and is meant for long-term management of hair loss in men and women with this condition. Alongside it, the company is developing VDMN, a dissolvable patch that uses immunotherapy to treat common warts, plus earlier programs aimed at alopecia areata, molluscum contagiosum, and atopic dermatitis.
Taken together, these programs are meant to serve dermatologists and aesthetic care providers who treat patients across age groups, as well as the broader dermatology research and clinical community.
Veradermics was founded in 2019 and is headquartered in New Haven, Connecticut. Its shares are listed on the NYSE under the ticker MANE.
Veradermics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.1, in the Neutral zone, up 4.5 points over five sessions.
Up 4.5 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 0 | Not available | |||
| Accumulation | 32 | +5.5% | +12.5% | ||
| Neutral (current zone) | 119 | +3.9% | +17.6% | ||
| Distribution | 21 | +0.4% | +0.5% | ||
| Selling | 0 | Not available | |||
Average MANE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Veradermics trades 0.7% below Gekko Fair Value of $130.60, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Veradermics shares are worth, recalculated every trading day.
$130.60
Gekko Fair Value, Nov 14, 2026
0.7% below fair value · About fair value
At the end of Aug 2026 the price was 32.2% below the estimate.
No open-market insider purchases were filed for Veradermics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for MANE in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in MANE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
2of the funds Gekko tracks hold MANE.
Veradermics beat the EPS estimate in 2 of its last 3 reports, moving 1.5% on average across the report.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 11, 2026 | −$0.58 est −$0.65 | — | −1.5% |
| May 12, 2026 | −$1.32 est −$0.56 | — | −0.9% |
| Feb 25, 2026 | −$1.62 est −$1.81 | — | −2.0% |
| Dec 3, 2025 | −$1.62 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Veradermics is $187.33, +44.5% from the last close, from 3 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 3 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Leerink Partners | $185 | +42.7% |
| Nov 10 | Citi | $175 | +35.0% |
| Nov 9 | Citi | $175 | +35.0% |
| Nov 9 | Leerink Partners | $150 | +15.7% |
| Oct 19 | Citi | $160 | +23.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Veradermics’s market cap is $5.47B and revenue of $0 over the last twelve months.
Coverage of Veradermics this week reads positive: 9 positive, 3 neutral and 4 negative headlines.
Veradermics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Veradermics’s market cap is $5.47B at the Nov 13, 2026 close of $129.66, with 42.20M shares outstanding.
The consensus analyst 12-month price target for Veradermics is $187.33, +44.5% from the last close. Of the 3 firms that rated the stock in the last 90 days, 3 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Veradermics is about fair value: the Nov 13, 2026 close of $129.66 is 0.7% below Gekko Fair Value of $130.60. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Veradermics’s 52-week high is $156.63 and its 52-week low is $32.00; it closed at $129.66 on Nov 13, 2026.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 0 of the 2 items with data read as supportive, 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.